Thisretrospective look at 674 patients receiving immune checkpoint inhibition for eight different cancer primary sites revealed the third of patients with high tumor mutational burden achieved significantly longer survival confirming this is a robust predictor of response. | Aggarwal, JAMA Netw Open 2023
